StevenPatrickMarsoMD

Cardiology • Leawood, KS

Interventional Cardiology

Executive Medical Director CVSL, HCA Midwest Health

Join to view full profile

Dr. Marso is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Marso's full profile

Already have an account?

Office
5100 West 110th Street
Leawood, KS 66211
Phone+1 913-253-3000

Education & Training

University of Missouri-Kansas City School of MedicineFellowship, Interventional Cardiology, 1999 - 2000
Cleveland Clinic FoundationFellowship, Cardiovascular Disease, 1996 - 1999
University of Virginia Medical CenterResidency, Internal Medicine, 1993 - 1996
University of Kansas School of MedicineClass of 1993

Certifications & Licensure

KS State Medical License 2000 - 2025
MO State Medical License 1999 - 2024
TX State Medical License 2014 - 2018

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Fellow (FACC) American College of Cardiology

Clinical Trials

Diabetes Genome Project: A Prospective Registry to Identify Genetic Variation Among Diabetic Patients Start of enrollment: 2002 Jul 01
Completed
The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel Start of enrollment: 2010 Oct 01
Completed
Phase 4
SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension Start of enrollment: 2011 Sep 01
Completed
Not Applicable
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) Start of enrollment: 2021 May 11
Active, not recruiting
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1207 citations
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar
The New England Journal of Medicine. 2016-11-10
59 citations
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure
Steven P. Marso, Florian M.M. Baeres, Stephen C. Bain, Bryan Goldman, Mansoor Husain
Journal of the American College of Cardiology. 2020-03-17
267 citations
Cholesterol Oxidation Products Are Sensitive and Specific Blood-Based Biomarkers for Niemann-Pick C1 Disease
Forbes D. Porter, David E. Scherrer, Michael H. Lanier, S. Joshua Langmade, Vasumathi Molugu
Science Translational Medicine. 2010-11-03

Journal Articles

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Steven P Marso, John B Buse, Diabetes Care

Press Mentions

New Medical Director of Cardiovascular Services at HCA Midwest HealthNovember 7th, 2016
Semaglutide Reduces Stroke, Mortality in Patients with DiabetesSeptember 20th, 2016
SUSTAIN-6: Cardiovascular Safety of Semaglutide in Type 2 DiabetesSeptember 16th, 2016
Join now to see all

Professional Memberships

American College of Cardiology - ACC
Member